<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342065</url>
  </required_header>
  <id_info>
    <org_study_id>Assuit University</org_study_id>
    <nct_id>NCT04342065</nct_id>
  </id_info>
  <brief_title>Pregabalin Versus Celecoxib on Sevoflurane and Analgesic Consumption in Spine Fixation Surgery</brief_title>
  <official_title>Efficacy of Pre-emptive Different Doses of Oral Pregabalin Versus Celecoxib on Sevoflurane and Analgesic Consumption in Patients Subjected for Elective Lumbar Spine Fixation Surgery: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Egypt Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South Egypt Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The anti-epileptic drugs such as gabapentin and other non-steroidal anti-inflammatory drugs
      (NSAID) such as celecoxib were used as a part of multimodal analgesia to control such pain.
      Gabapentin is an anticonvulsant drug that has analgesic effect in post-herpetic neuralgia,
      diabetic neuropathy, and neuropathic pain. Celecoxib is one of the NSAIDs, that its analgesic
      effect is reported in various studies by cyclooxygenase-2 (COX-2) inhibitor.

      The aim of this randomized double-blinded study was to asses and compare the efficacy of
      using gabapentin versus celecoxib as a part of multimodal analgesia in perioperative
      hemodynamic control and pain relief in patients underwent posterior approach lumbar spine
      disc fixation surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">February 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain control</measure>
    <time_frame>Change from Baseline Visual Analogue Scale every 4 hours for 48 hours (0=no pain 10=most sever pain)</time_frame>
    <description>Visual Analogue Scale for pain measurement.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Post-Operative Pain</condition>
  <arm_group>
    <arm_group_label>Group (G)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received gabapentin 300 mg capsule 2 hours preoperative and the same dose 6 hours postoperative.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group (C)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib capsules</intervention_name>
    <description>received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.</description>
    <arm_group_label>Group (C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 150mg</intervention_name>
    <description>received Pregabalin 150mg 2 hours preoperative and the same dose 6 hours postoperative.</description>
    <arm_group_label>Group (G)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American society of anesthesiologists (ASA) I and II, aged between 21-60 years old
             scheduled to undergo elective posterior approach lumbar spine disc surgery

        Exclusion Criteria:

          -  Patients with a known sensitivity to celecoxib or pregabalin, psychotic disorder or
             cognitive impairment, history of drug dependency or substance addiction, history of
             chronic medical disease, the presence of coagulation disorders or pregnancy, were
             excluded from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>South Egypt Cancer Institute, Assiut University, Arab Republic of Egypt</name>
      <address>
        <city>Assiut</city>
        <zip>0020</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Research Consultants, Inc.</investigator_affiliation>
    <investigator_full_name>Alaa Ali M. Elzohry</investigator_full_name>
    <investigator_title>Lecturer of Anesthesia, ICU and Pain Relief</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

